Sunday, February 14, 2021

Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug according to the results from a phase 3 clinical trial.

from Top Health News -- ScienceDaily https://ift.tt/2Zjxsqe
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

A major risk of breast cancer screening may have been overestimated for decades

A new analysis suggests mammograms may lead to far less breast cancer overdiagnosis than some earlier studies indicated. Researchers reexami...